ABSTRACT
Objective: There are controversial data regarding the utility of statins in hospitalized COVID-19 patients. This study aimed to assess the efficacy of statins on clinical outcomes of patients hospitalized with COVID-19. Methods: A non-randomized clinical trial was performed among confirmed COVID-19 patients who were admitted to the BooAli hospital in Tehran, Iran. The intervention group received atorvastatin 20 mg orally once daily plus standard of care, while the control group received standard of care alone. The primary endpoints were clinical improvement rate at day 7 as well as in-hospital mortality rate. The secondary endpoints were the duration of hospitalization, the number of intensive care unit (ICU) admissions, the number of patients who needed invasive mechanical ventilation, the incidence of acute respiratory distress syndrome (ARDS), and the reduction of inflammatory markers. Result: In total 94 patients were enrolled (treatment group: 41 patients, control group: 53 patients). The results showed that nearly 59% of patients who received atorvastatin manifested clinical improvement within 7 days compared to 62% of patients in the control group (P > 0.05). There was no significant difference between treatment and control groups in terms of in-hospital mortality, duration of hospitalization, ICU admissions, need for invasive mechanical ventilation, and incidence of ARDS. Conclusion: Atorvastatin 20 mg daily in hospitalized OOVID-19 patients was not associated with significant changes in clinical improvement of patients within 7 days, in-hospital mortality rate, and other clinical outcomes.